Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 631 AL 645

Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)

Luchsinger JA, Devanand D, Goldberg TE, Cammack S, Hernández-Santiago G, Oishi K, Jagust W, Baker S, Landau S, Yenokyan G, Betz J, Mayers S, Eyzaguirre LM, Hanley D; MAP Study Group.

Alzheimer Dis Assoc Disord. 2025 Apr-Jun 01;39(2):123-133. doi: 10.1097/WAD.0000000000000677. Epub 2025 May 28.

Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial

Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, Carter B, Aarsland D.

Age Ageing. 2025 May 31;54(6):afaf149. doi: 10.1093/ageing/afaf149.

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease

Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, Zhang Z, Brubaker M, Grossberg GT.

Curr Med Res Opin. 2025 Aug;41(8):1523-1534. doi: 10.1080/03007995.2025.2552278. Epub 2025 Sep 5.

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M.

Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.

Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms

Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L, Battino M, Giampieri F, Quiles JL, Forbes-Hernández TY.

Int J Mol Sci. 2025 Oct 31;26(21):10631. doi: 10.3390/ijms262110631.

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial

Shah A, Estilo A, Sheridan PL, Kalu U, Chen D, Chang D, Slomkowski M, Lee D, Hefting N, Hobart M, Behl S, Such P, Brubaker M, Grossberg GT.

CNS Drugs. 2025 Oct;39(10):1011-1023. doi: 10.1007/s40263-025-01200-9. Epub 2025 Jul 19.

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Kutzsche J, Cosma NC, Kauselmann G, Fenski F, Bieniek C, Bujnicki T, Pils M, Bannach O, Willbold D, Peters O.

Nat Commun. 2025 May 6;16(1):4180. doi: 10.1038/s41467-025-59295-z.

Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer's disease

Kim HB, Yoo S, Kwak H, Ma SX, Kim R, Lee M, Ha N, Pyo S, Kwon SG, Cho EH, Lee SM, Jang J, Kim WK, Park HC, Baek M, Park Y, Park JY, Park JW, Hwang SW, Hwang JI, Seong JY.

Alzheimers Res Ther. 2025 Jul 21;17(1):168. doi: 10.1186/s13195-025-01813-8.

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, Doherty T, Tian L, Raman R, Aisen PS, Kramer LD, Irizarry MC, Dhadda S.

Alzheimers Dement. 2025 Sep;21(9):e70702. doi: 10.1002/alz.70702.

Eligibility for donanemab trial in a population-based study of cognitive aging

Jones KE, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr, Vemuri P, Schwarz CG, Lowe VJ, Knopman DS, Petersen RC, Graff-Radford J, Vassilaki M.

J Prev Alzheimers Dis. 2025 Apr;12(4):100088. doi: 10.1016/j.tjpad.2025.100088. Epub 2025 Feb 17.

Japanese participant data from three gantenerumab trials in early Alzheimer's disease

Asada T, Thanasopoulou A, Delmar P, Wojtowicz J, Smith J, Yoshiyama Y, Yokoi K, Watanabe C, Isozaki M, Ozaki R, Ishida T, Tatsuda H, Tamaoka A.

Alzheimers Dement. 2025 Apr;21(4):e70192. doi: 10.1002/alz.70192.

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.

Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776.

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis

Hsu CW, Hsu TW, Kao YC, Lin YH, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Yang FC, Tsai CK, Yu CL, Tu YK, Liang CS.

J Prev Alzheimers Dis. 2025 Sep;12(8):100195. doi: 10.1016/j.tjpad.2025.100195. Epub 2025 May 1.

Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia

Nakamura Y, Adachi J, Hirota N, Iba K, Sasajima C, Shimizu K, Nakai M, Takahashi K.

Alzheimers Dement. 2025 Jul;21(7):e70522. doi: 10.1002/alz.70522.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias